Adagraxibu latest price in 2024

Adagrasib is a new type of anti-cancer drug, also known as MRTX849. It is a small molecule targeted drug targeting cancers with K-Ras mutations. K-RasMutation is a common cancer driver gene mutation that is found in a variety of cancers, such as non-small cell lung cancer, colorectal cancer, etc. Traditionally, K-Ras mutations have been considered difficult to treat because they render cancer cells resistant to conventional treatments, such as targeted therapies and chemotherapy.

Since adagrasib is not yet available on the domestic market, patients are currently unable to purchase it directly domestically and must obtain it through overseas channels. The price of the original Adagrasibu drug produced in the United States is extremely high, reaching more than 180,000 yuan, making it unaffordable for ordinary families. But what is gratifying is that foreign generic drugs have recently come out. Among them, the generic drug of adagrasibu launched by Lucius Pharmaceuticals in Laos is relatively affordable, priced at about four to five thousand yuan per box, and its pharmaceutical ingredients are basically the same as the original drug.

However, the emergence of adagrasib has brought new hope to patients withK-Ras mutations. It works by inhibiting the activation of Ras protein, thereby blocking the signaling pathway for cancer cell proliferation. The drug, which targets the K-Ras mutation, is considered a breakthrough treatment because it targets a type of cancer that has long been considered ineffective in treating it.

Clinical trials have shown that adagrasib has shown encouraging efficacy in some patients. Although there are still some challenges, such as drug resistance and side effects, its emergence provides a new treatment option for patients with K-Ras mutations. This gives scientists and doctors confidence that more drugs targeting K-Ras mutations will be developed in the future, thereby bringing better therapeutic effects to these patients.